The tissue cultures have been grown in the laboratories of Drs. Bemd 
Gansbacher and Neil Bander. The tumor cells have been infected with the 
retroviral vector, NAP-AD/IL2. Cells that secrete IL-2 will be irradiated (10,000 
rads) and given as a series of four vaccinations. If a patient has a clinical 
response as defined in section 10.0, then additional boosters will be given up to 
one year in duration or until progression of disease. Six patients will receive low 
dose vaccine and the additional six will receive high dose (see section 7.1). 
3.0 CRITERIA FOR PATIENT ELIGIBILITY 
Patients must fulfill the following criteria to be eligible for study admission: 
3.1 Patients with histologic confirmation of metastatic renal cell carcinoma at 
MSKCC. 
3.2 Kamofsky performance status greater than or equal to 70% and life 
expectancy greater than 4 months. 
3.3 Adequate hematologic function with WBC _> 3000/mm 3 , absolute 
lymphocyte count > 1000/mm 3 , hemoglobin _> 9, and platelets _> 
100,000/mm 3 . 
3.4 Adequate renal and hepatic function (serum creatinine <_ 2.5 mg/dl and 
bilirubin < 1.7 mg/dl). 
3.5 At least 4 weeks since any prior radiation therapy, immunotherapy, or 
chemotherapy (6 weeks for nitrosoureas), and full recovery from such 
treatment. 
3.6 The ability to give written informed consent. 
3.7 Age _> 18 years. 
3.8 No history of other concurrent malignancies except basal cell carcinoma, 
squamous cell carcinoma of the skin, or carcinoma-in-situ of the cervix. 
3.9 No systemic steroids for at least one week prior to treatment. 
3.10 Selection of patients with minimal tumor burden is encouraged. All 
patients must have undergone a nephrectomy or have a non bulky tumor ( 
less or equal to 5 cm). 
3.11 Patients must be HLA-A2 positive. 
[ 924 ] 
Recombinant DNA Research, Volume 15 
